메뉴 건너뛰기
Journal of Clinical Oncology
Volumn 27, Issue 34, 2009, Pages 5677-5679
Stop and go: Yes or no?
Author keywords

[No Author keywords available]
Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;
EID: 73349138901     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.24.5209     Document Type: Editorial
Times cited : (21)
References (6)
  • 1
    • 73349089651 scopus 로고    scopus 로고
    • Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 study
    • Chibaudel B, Maindrault-Goebel F, Lledo G, et al: Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 study. J Clin Oncol 27:5727-5733, 2009
    • (2009) J Clin Oncol , vol.27 , pp. 5727-5733
    • Chibaudel, B.1    Maindrault-Goebel, F.2    Lledo, G.3
  • 2
    • 33644843853 scopus 로고    scopus 로고
    • OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer: A GERCOR study
    • Tournigand C, Cervantes A, Figer A, et al: OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer: A GERCOR study. J Clin Oncol 24:394-400, 2006
    • (2006) J Clin Oncol , vol.24 , pp. 394-400
    • Tournigand, C.1    Cervantes, A.2    Figer, A.3
  • 3
    • 42949149159 scopus 로고    scopus 로고
    • Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study
    • Saltz LB, Clarke S, Diaz-Rubio E, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 26:2013-2019, 2008
    • (2008) J Clin Oncol , vol.26 , pp. 2013-2019
    • Saltz, L.B.1    Clarke, S.2    Diaz-Rubio, E.3
  • 4
    • 65749088446 scopus 로고    scopus 로고
    • Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): Final results of the phase III CONcePT trial
    • suppl; abstr 4010, 180s
    • Grothey A, Hart LL, Rowland KM, et al: Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): Final results of the phase III CONcePT trial. J Clin Oncol 26:180s, 2008 (suppl; abstr 4010)
    • (2008) J Clin Oncol , vol.26
    • Grothey, A.1    Hart, L.L.2    Rowland, K.M.3
  • 5
    • 77949524888 scopus 로고    scopus 로고
    • mFOLFOX-bevacizumab or XELOX-bevacizumab then bevacizumab (B) alone or with erlotinib (E) in first-line treatment of patients with metastatic colorectal cancer (mCRC): Interim safety analysis of DREAM study
    • suppl; abstr 4077, 15s
    • Tournigand C, Samson B, Scheithauer W, et al: mFOLFOX-bevacizumab or XELOX-bevacizumab then bevacizumab (B) alone or with erlotinib (E) in first-line treatment of patients with metastatic colorectal cancer (mCRC): Interim safety analysis of DREAM study. J Clin Oncol 27:15s, 2009 (suppl; abstr 4077)
    • (2009) J Clin Oncol , vol.27
    • Tournigand, C.1    Samson, B.2    Scheithauer, W.3
  • 6
    • 68949094312 scopus 로고    scopus 로고
    • Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy
    • Kopetz S, Chang GJ, Overman MJ, et al: Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27:3677-3683, 2009
    • (2009) J Clin Oncol , vol.27 , pp. 3677-3683
    • Kopetz, S.1    Chang, G.J.2    Overman, M.J.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.